补肾明目丸对糖尿病肾病Ⅲ期（肾虚血瘀证）患者TGF-β1、PKC的影响
发布时间：2019-06-19 04:23
【摘要】：目的:研究补肾明目丸对DKDⅢ期(肾虚血瘀证)患者TGF-β1、PKC的影响及其对肾脏的保护作用。方法:筛选出66例符合纳入标准的DKDⅢ期(肾虚血瘀证)患者,按照随机数字法分为治疗组(33例)和对照组(33例),治疗组在基础治疗基础上加补肾明目丸,对照组只给予基础治疗,疗程12周。以中医症候积分、Hb Alc、U-MA、尿β2-MG、Cysc、转化生长因子β1(TGF-β1)、蛋白激酶C(PKC)作为疗效评价指标,观察其疗效。结果:1.中医症候积分:治疗后两组中医证候积分与治疗前相比都有显著下降(P0.01);但两组治疗后相比治疗组下降的更加明显(P0.05);治疗组总有效率为87.1%,高于对照组的62.5%(P0.05)。2.U-MA、尿β2-MG、Cysc比较:治疗组治疗后U-MA、尿β2-MG、Cysc明显低于治疗前(P0.01);对照组治疗后U-MA、Cysc明显低于治疗前(P0.01);对照组治疗后尿β2-MG低于治疗前(P0.05);治疗组治疗后U-MA、尿β2-MG、Cysc与对照组治疗后相比,差异有统计学意义(P0.05)。3.血清TGF-β1:治疗组治疗后TGF-β1明显低于治疗前(P0.01);对照组治疗后低于治疗前(P0.05);两组病人治疗后相比,差异有统计学意义(P0.01)。4.血清PKC:两组治疗后PKC水平均明显低于治疗前(P0.01);治疗组治疗后低于对照组治疗后,差异有统计学意义(P0.05)。5.Hb Alc:两组Hb Alc治疗后均明显低于治疗前(P0.01);但治疗组治疗后与对照组治疗后相比差异无统计学意义(P0.05)。6.血脂:两组治疗后LDL-C、TG与治疗前比较,差异无统计学意义(P0.05)。结论:补肾明目丸可以明显的改善糖尿病肾病(肾虚血瘀证)患者的早期临床相关症状。补肾明目丸能够降低糖尿病肾病患者U-MA、尿β2-MG、Cysc、TGF-β1、PKC的水平,并且疗效确切。
[Abstract]:Aim: to study the effect of Bushen Mingmu Pill on TGF- 尾 1 and PKC in patients with DKD stage III (kidney deficiency and blood stasis syndrome) and its protective effect on kidney. Methods: 66 patients with DKD stage III (kidney deficiency and blood stasis syndrome) were randomly divided into treatment group (n = 33) and control group (n = 33). The treatment group was supplemented with Bushen Mingmu pill on the basis of basic treatment, and the control group was only given basic treatment for 12 weeks. Hb Alc,U-MA, urine 尾 2-MG,Cysc, transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC) were used as therapeutic indexes to observe the curative effect of TCM syndrome score, urine 尾 2-transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC). Result: 1. TCM syndrome score: after treatment, the scores of TCM syndromes in both groups were significantly lower than those before treatment (P 0.01), but after treatment, the scores of TCM syndromes in the two groups were more obvious than those in the treatment group (P 0.05). The total effective rate of the treatment group was 87.1%, which was higher than that of the control group (62.5%). 2.U 鈮，
本文编号：2502086
[Abstract]:Aim: to study the effect of Bushen Mingmu Pill on TGF- 尾 1 and PKC in patients with DKD stage III (kidney deficiency and blood stasis syndrome) and its protective effect on kidney. Methods: 66 patients with DKD stage III (kidney deficiency and blood stasis syndrome) were randomly divided into treatment group (n = 33) and control group (n = 33). The treatment group was supplemented with Bushen Mingmu pill on the basis of basic treatment, and the control group was only given basic treatment for 12 weeks. Hb Alc,U-MA, urine 尾 2-MG,Cysc, transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC) were used as therapeutic indexes to observe the curative effect of TCM syndrome score, urine 尾 2-transforming growth factor 尾 1 (TGF- 尾 1) and protein kinase C (PKC). Result: 1. TCM syndrome score: after treatment, the scores of TCM syndromes in both groups were significantly lower than those before treatment (P 0.01), but after treatment, the scores of TCM syndromes in the two groups were more obvious than those in the treatment group (P 0.05). The total effective rate of the treatment group was 87.1%, which was higher than that of the control group (62.5%). 2.U 鈮，
本文编号：2502086
本文链接：https://www.wllwen.com/zhongyixuelunwen/2502086.html
